Researchers at the Institute of Process Engineering (Chinese Academy of Sciences) published a Cell paper introducing the ferritin aggregation cell engager (FACE), a biomimetic, ferritin‑based platform that strengthens CAR‑T cell engagement with leukemia cells via CD71 targeting. FACE is applied as a culture supplement during CAR‑T manufacturing and creates post‑infusion links between CAR‑T cells and tumor cells, improving recognition when antigen expression is low. Preclinical data including patient‑derived xenograft models showed FACE enhanced efficacy, reduced required cell doses, and lowered cytokine release syndrome risk. The platform relies on endogenous proteins and FDA‑approved polymers and can be integrated into existing manufacturing workflows without additional genetic engineering of CAR constructs. The approach offers a manufacturing‑friendly route to increase CAR‑T potency against antigen‑modulated relapse and could be applied broadly to hematologic indications where CD71 is expressed.